We studied structural and immunological properties of the SARS-CoV M (membrane) protein, based on comparative analyses of sequence features, phylogenetic investigation, and experimental results. The M protein is predicted to contain a triple-spanning transmembrane (TM) region, a single N-glycosylation site near its N-terminus that is in the exterior of the virion, and a long C-terminal region in the interior. The M protein harbors a higher substitution rate (0.6% correlated to its size) among viral open reading frames (ORFs) from published data. The four substitutions detected in the M protein, which cause non-synonymous changes, can be classified into three types. One of them results in changes of pI (isoelectric point) and charge, affecting antigenicity. The second changes hydrophobicity of the TM region, and the third one relates to hydrophilicity of the interior structure. Phylogenetic tree building based on the variations of the M protein appears to support the non-human origin of SARS-CoV. To investigate its immunogenicity, we synthesized eight oligopeptides covering 69.2% of the entire ORF and screened them by using ELISA (enzyme-linked immunosorbent assay) with sera from SARS patients. The results confirmed our predictions on antigenic sites.
Amino Acid Sequence ; Base Sequence ; Cluster Analysis ; Enzyme-Linked Immunosorbent Assay ; Immunoassay ; Molecular Sequence Data ; Mutation ; genetics ; Oligopeptides ; Phylogeny ; Protein Structure, Tertiary ; SARS Virus ; genetics ; Sequence Alignment ; Sequence Analysis, DNA ; Viral Matrix Proteins ; chemistry ; genetics ; immunology

Successful preemptive therapy for cytomegalovirus (CMV) infection in transplant patients depends on the availability of sensitive, specific, and timely diagnostic tests for CMV infection. Although the pp65 antigenemia assay has been widely used for this purpose, real-time quantification of CMV DNA has recently been recognized as an alternative diagnostic approach. However, the guidelines for antiviral therapy based on real-time quantitative polymerase chain reaction (RQ-PCR) have yet to be established. From November 2004 to March 2005, a total of 555 whole blood samples from 131 hematopoietic stem cell transplant (HSCT) recipients were prospectively collected. RQ-PCR was conducted using an Artus(R) CMV LC PCR kit (QIAGEN). Both qualitative and quantitative correlations were drawn between the two methods. Exposure to the antiviral agent influenced the results of the two assays. Additionally, the discrepancy was observed at low levels of antigenemia and CMV DNA load. Via ROC curve analysis, the tentative cutoff value for preemptive therapy was determined to be approximately 2x10(4) copies/mL (sensitivity, 80.0%; specificity, 50.0%) in the high risk patients, and approximately 3x10(4) copies/mL (sensitivity, 90.0%; specificity, 70.0%) in the patients at low risk for CMV disease. Further study to validate the optimal cutoff value for the initiation of preemptive therapy is currently underway.
Adolescent ; Adult ; Child ; Child, Preschool ; Cytomegalovirus/genetics/*isolation & purification ; Cytomegalovirus Infections/*diagnosis/therapy ; DNA, Viral/*blood ; Female ; *Hematopoietic Stem Cell Transplantation ; Humans ; Infant ; Male ; Middle Aged ; Phosphoproteins/analysis/immunology ; Polymerase Chain Reaction/*methods ; ROC Curve ; Reagent Kits, Diagnostic ; Sensitivity and Specificity ; Viral Matrix Proteins/analysis/immunology